Clinical trial
An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients
NCT04604782 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients
- Lead sponsor
- GE Healthcare
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- May 20, 2021
- Completion date
- December 31, 2026
- Enrollment
- 54 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.